<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852024000500003</article-id>
<article-id pub-id-type="doi">10.48193/3adrvz79</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Epidemiologia y características clínicas de los tumores vesicales registrados en un hospital de referencia de la Península de Yucatán]]></article-title>
<article-title xml:lang="en"><![CDATA[Epidemiology and clinical characteristics of bladder tumors recorded in a reference hospital in the Yucatan Peninsula]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Monzón Falconi]]></surname>
<given-names><![CDATA[Juan Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreiro Olvera]]></surname>
<given-names><![CDATA[Francisco Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza Arcila]]></surname>
<given-names><![CDATA[Manuel Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores Tapia]]></surname>
<given-names><![CDATA[Juan Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esqueda Mendoza]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Nuricumbo]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretaría de Salud Hospital Regional de Alta Especialidad de la Peninsula de Yucatán ]]></institution>
<addr-line><![CDATA[ Yucatán]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>10</month>
<year>2024</year>
</pub-date>
<volume>84</volume>
<numero>5</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852024000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852024000500003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852024000500003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  en México, se encuentra en el cuarto lugar de presentación de los tumores urológicos con el 14.4 % detrás del cáncer de próstata, testículo y riñón, y con una relación hombre:mujer de 3.8:1. El cáncer vesical es una de las principales causas de consulta en pacientes con hematuria macroscópica formadoras de coágulos, por lo cual siempre debe tenerse como diagnóstico de exclusión en este tipo de pacientes, debido a la progresión de la misma y la afección en la morbi-mortalidad si se detectan en estadios avanzados.  Objetivos:  determinar la prevalencia y características clínicas de los casos registrados de cáncer vesical en el servicio de urología.  Material y métodos:  estudio descriptivo, observacional, transversal en el que se evaluaran los expedientes clínicos de los pacientes de los casos registrados de cáncer vesical en el servicio de urología del Hospital Regional de Alta Especialidad de la Península de Yucatán el periodo enero 2017 a julio del 2021.  Resultados:  de un total de 453 tumores genitourinarios, el 15.62 %, 29 pacientes fueron diagnosticados con cáncer vesical con un seguimiento médico de 4 años, el tumor vesical es prevalentemente en hombres con una relación de 3.83 hombres por cada mujer, con una media de edad al diagnóstico de 65 años. Dentro de los factores de riesgo modificables, el tabaquismo es la afectación principal con el 44.8 %. De acuerdo con la clasificación histológica la estirpe predominante fue el carcinoma urotelial. La evolución del tiempo de inicio de sintomatología hasta obtener atención medica por parte de los pacientes fue de 11.9 meses. Detectándose en un estadio T4 en el 27.59 % de los casos, con una mortalidad del 6.9 %.  Conclusión:  el cáncer vesical es la tercera neoplasia urológica más frecuentes con una gran afección en la calidad de vida de los pacientes y con una morbimortalidad elevada si se detecta en estadios avanzados requiriendo procedimientos quirúrgicos muy agresivos y con alto riesgo de complicaciones.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  in Mexico, bladder tumors rank fourth in urological tumor presentation, accounting for 14.4 % of cases, following prostate, testicular, and kidney cancer. The male-to-female ratio is 3.8:1. Bladder cancer is one of the main causes of consultation in patients with macroscopic hematuria and clot formation. Therefore, it should always be considered as an exclusion diagnosis in these patients due to its potential progression and impact on morbidity and mortality if detected in advanced stages.  Objectives:  to determine the prevalence and clinical characteristics of registered cases of bladder cancer in the urology department.  Materials and methods:  this is a descriptive, observational, cross-sectional study that will evaluate the medical records of patients with registered cases of bladder cancer in the Urology Department of the Hospital Regional de Alta Especialidad de la Península de Yucatán in Mexico, from from January 2017 to July 2021.  Results:  of total 453 genitourinary tumors, 15.62 %, 29 patients with bladder tumor and a 4-year medical follow-up were included, bladder tumor is predominantly found in men with a male-to-female ratio of 3.83 men per woman. The mean age at diagnosis is 65 years. Among modifiable risk factors, smoking is the main factor affecting 44.8 % of the cases. According to the histological classification, the predominant subtype was urothelial carcinoma. The average time from symptom onset to medical attention by the patients was 11.9 months. T4 stage was detected in 27.59 % of the cases, with a mortality rate of 6.9 %.  Conclusion:  bladder cancer is one of the three most common urological cancers, affecting the quality of life and with a high morbidity and mortality when detected at advanced stages, requiring aggressive surgical procedures with a high risk of complications.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[vertical cancer]]></kwd>
<kwd lng="en"><![CDATA[prevalence]]></kwd>
<kwd lng="en"><![CDATA[vertical tumors]]></kwd>
<kwd lng="es"><![CDATA[cancer versical]]></kwd>
<kwd lng="es"><![CDATA[prevalencia]]></kwd>
<kwd lng="es"><![CDATA[tumores versicales]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la Rosa-Cisneros]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Viveros-Contreras]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Aguilar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-León]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Arellano-Cuadros]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Carrillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experiencia en el tratamiento de cáncer vesical]]></article-title>
<source><![CDATA[Revista Mexicana de Urología]]></source>
<year>2015</year>
<volume>75</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>58-63</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedano-Basilio]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Mayorga-Gómez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Garza-Sainz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cornejo-Dávila]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Uberetagoyena-Tello de Meneses]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Palmeros-Rodríguez]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología de los tumores genitourinarios en una década]]></article-title>
<source><![CDATA[Revista Mexicana de Urología]]></source>
<year>2016</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131-40</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richters]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aben]]></surname>
<given-names><![CDATA[KKH]]></given-names>
</name>
<name>
<surname><![CDATA[Kiemeney]]></surname>
<given-names><![CDATA[LALM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The global burden of urinary bladder cancer: an update]]></article-title>
<source><![CDATA[World Journal of Urology]]></source>
<year>2020</year>
<volume>38</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1895-904</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA: a cancer journal for clinicians]]></source>
<year>2018</year>
<volume>68</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>394-424</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antoni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Znaor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2017</year>
<volume>71</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-108</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanli]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Dobruch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Knowles]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alemozaffar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bladder cancer]]></article-title>
<source><![CDATA[Nature Reviews. Disease Primers]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>17022</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Afferi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Moschini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mostafid]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Porten]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Psutka]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology, Screening, and Prevention of Bladder Cancer]]></article-title>
<source><![CDATA[European Urology Oncology]]></source>
<year>2022</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>628-39</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenfant]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cancel-Tassin]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gazut]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Compérat]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rouprêt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cussenot]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis]]></article-title>
<source><![CDATA[BJU international]]></source>
<year>2021</year>
<volume>127</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>375-83</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saginala]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Barsouk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aluru]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Rawla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Padala]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Barsouk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of Bladder Cancer]]></article-title>
<source><![CDATA[Medical Sciences (Basel, Switzerland)]]></source>
<year>2020</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenis]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Lec]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Chamie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mshs]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bladder Cancer: A Review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>324</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1980-91</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Witjes]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bruins]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Cathomas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Compérat]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Gakis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2021</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82-104</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cumberbatch]]></surname>
<given-names><![CDATA[MGK]]></given-names>
</name>
<name>
<surname><![CDATA[Jubber]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Esperto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Kamat]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2018</year>
<volume>74</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>784-95</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollenbeck]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Dunn]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hollingsworth]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Skolarus]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delays in diagnosis and bladder cancer mortality]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2010</year>
<volume>116</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>5235-42</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Babjuk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Capoun]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Compérat]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Dominguez Escrig]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2022</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-94</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rozanec]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Secin]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiología, etiología, prevención del cáncer vesical]]></article-title>
<source><![CDATA[Archivos Españoles de Urología]]></source>
<year>2020</year>
<volume>73</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>872-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
